Abstract
Pirbenicillin {6-[d-2-phenyl-2(N-4-pyridylformimidoylaminoacetamido) -acetamido]-penicillanic acid} showed broad-spectrum antibacterial activity in vitro and also in the treatment of experimental infections after parenteral administration to mice. Against Pseudomonas aeruginosa, a three- to fourfold potency advantage over carbenicillin was seen both in vitro and in vivo. The in vitro antibacterial spectrum of pirbenicillin includes Escherichia coli, Serratia, Citrobacter, and Enterobacter isolates, against which it exhibited minimal inhibitory concentration values comparable to those of carbenicillin. However, mice infected with E. coli and Serratia were protected at doses of pirbenicillin that were two to four times lower than those required of carbenicillin. Pirbenicillin was more active than carbenicillin against gram-positive bacteria, especially Streptococcus faecalis. It was less active than carbenicillin against Proteus spp. and was inactive against ampicillin-resistant E. coli strains. Pirbenicillin was bactericidal at concentrations generally equal to or only two-fold higher than the minimal inhibitory concentration. With appropriately buffered media, pirbenicillin demonstrated eight- and fourfold better minimal bactericidal concentration values towards Pseudomonas isolates than those of carbenicillin and ticarcillin, respectively.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andriole V. T. Antibiotic synergy in experimental infection with Pseudomonas. II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin or gentamicin. J Infect Dis. 1974 Feb;129(2):124–133. doi: 10.1093/infdis/129.2.124. [DOI] [PubMed] [Google Scholar]
- Andriole V. T. Synergy of carbenicillin and gentamicin in experimental infection with Pseudomonas. J Infect Dis. 1971 Dec;124 (Suppl):S46–S55. doi: 10.1093/infdis/124.supplement_1.s46. [DOI] [PubMed] [Google Scholar]
- English A. R., Retsema J. A., Ray V. A., Lynch J. E. Carbenicillin indanyl sodium, an orally active derivative of carbenicillin. Antimicrob Agents Chemother. 1972 Mar;1(3):185–191. doi: 10.1128/aac.1.3.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Klastersky J., Cappel R., Daneau D. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother. 1972 Dec;2(6):470–475. doi: 10.1128/aac.2.6.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Klastersky J., Cappel R., Debusscher L. Evaluation of gentamicin with carbenicillin in infections due to gram-negative bacilli. Curr Ther Res Clin Exp. 1971 Mar;13(3):174–181. [PubMed] [Google Scholar]
- Phair J. P., Watanakunakorn C., Bannister T. In vitro susceptibility of Pseudomonas aeruginosa to carbenicillin and the combination of carbenicillin and gentamicin. Appl Microbiol. 1969 Sep;18(3):303–306. doi: 10.1128/am.18.3.303-306.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
- SHERRIS J. C., SHOESMITH J. G., PARKER M. T., BRECKON D. Tests for the rapid breakdown of arginine by bacteria: their use in the identification of pseudomonads. J Gen Microbiol. 1959 Oct;21:389–396. doi: 10.1099/00221287-21-2-389. [DOI] [PubMed] [Google Scholar]
- Wald E. R., Standiford H. C., Tatem B. A., Calia F. M., Hornick R. B. BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1975 Mar;7(3):336–340. doi: 10.1128/aac.7.3.336. [DOI] [PMC free article] [PubMed] [Google Scholar]